Lewicki Sławomir, Zdanowski Robert, Krzyżowska Małgorzata, Lewicka Aneta, Dębski Bogdan, Niemcewicz Marcin, Goniewicz Mariusz
Department of Regenerative Medicine, Military Institute of Hygiene and Epidemiology, Warsaw, Poland.
Department of Hygiene and Physiology, Military Institute of Hygiene and Epidemiology, Warsaw, Poland.
Ann Agric Environ Med. 2014;21(2):331-5. doi: 10.5604/1232-1966.1108599.
Diabetes and obesity are diseases characterized by their increasing incidence every year. When comparing with healthy subjects, the serum levels of chromium (Cr) are lowered in these two diseases. Several studies conducted in laboratory animals with experimentally- induced diabetes demonstrated that supplementation with chromium ions (III) decreased glucose concentration in the blood, reduced the probability of atherosclerosis and heart attack, lowered the levels of cholesterol and low density lipoprotein (LDL). The Importance of chromium is actually challenged due to lack of clear manifestations of Cr deficiency in humans and animals.
The aim of this review was to present current knowledge about Cr its role in the organism and possible mechanisms of its action also in metabolic disorders such as diabetes or obesity.
In the last decade, Cr was established to be rather a beneficial than essential trace element in mammals, and has gained popularity as a nutritional supplement and a component of many multivitamin/mineral formulations, fortified food and energy drinks. Cr supplements are widespread for diabetes and obesity treatment, despite conflicting reports on its efficacy. It was suggested that Cr shows a beneficial influence upon glucose and lipid disturbances.
The recent clinical trials provided evidence both in favor and against the importance of Cr in healthy and ill organisms. Unfortunately, also the molecular mechanism by which chromium affects glucose and lipid metabolism is still unclear. Beneficial effects of diet supplementation with different sources of Cr³⁺ can be potentially explained by rather pharmacological than nutritional effects.
糖尿病和肥胖症是发病率逐年上升的疾病。与健康受试者相比,这两种疾病患者的血清铬(Cr)水平较低。在实验性诱导糖尿病的实验动物中进行的多项研究表明,补充铬离子(III)可降低血液中的葡萄糖浓度,降低动脉粥样硬化和心脏病发作的概率,降低胆固醇和低密度脂蛋白(LDL)水平。由于人和动物缺乏明显的铬缺乏表现,铬的重要性实际上受到了质疑。
本综述的目的是介绍关于铬的现有知识,其在生物体中的作用以及其在糖尿病或肥胖症等代谢紊乱中的可能作用机制。
在过去十年中,铬在哺乳动物中被确定为一种有益而非必需的微量元素,并作为营养补充剂以及许多多种维生素/矿物质配方、强化食品和能量饮料的成分而受到欢迎。尽管关于铬补充剂疗效的报道相互矛盾,但铬补充剂在糖尿病和肥胖症治疗中仍广泛使用。有人认为铬对葡萄糖和脂质紊乱有有益影响。
最近的临床试验提供了支持和反对铬在健康和患病生物体中重要性的证据。不幸的是,铬影响葡萄糖和脂质代谢的分子机制仍不清楚。补充不同来源的Cr³⁺对饮食的有益影响可能更多地是由药理作用而非营养作用来解释。